Sponsor:
BioInvent International AB
Code:
NCT04752826
Conditions
Advanced Malignancies
Ovarian Cancer
T-cell Lymphoma
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BI-1808
Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations